Overview

Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's doxycycline monohydrate 150 mg tablets to Par's Adoxa® 150 mg tablets following a single, oral 150 mg (1 x 150 mg) dose administered under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Doxycycline